November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Umang Swami: Patient-level analysis of ph3 SWOG 1216 trial in mHSPC
Nov 10, 2024, 03:09

Umang Swami: Patient-level analysis of ph3 SWOG 1216 trial in mHSPC

Umang Swami, Assistant Professor in the Division of Oncology at the Huntsman Cancer Institute, shared on X:

“Just in European Urology Oncology

In patient-level analysis of ph3 SWOG 1216 trial in mHSPC Prostate Cancer. Higher BMI associated with high OS. Helpful data for patient counseling/prognostication.”

Umang Swami

Shilpa Gupta, Director of Genitourinary Oncology, a staff member in Hematology and Oncology and a Professor of Medicine at Cleveland Clinic, shared this post on X, adding:

“Huge congrats Umang Swami, Neeraj Agarwal on leading this important work demonstrating association of higher BMI and better OS in SWOG S1216 trial in mHSPC.”

Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216

Authors: Umang Swami, Yeonjung Jo, Arshit Narang, Melissa Plets, Chadi Hage Chehade, Georges Gebrael, Shilpa Gupta, Zin Myint, Catherine Tangen, Primo N. Lara Jr., Ian M. Thompson Jr.,  Maha H.A. Hussain, Tanya B. Dorff, Seth P. Lerner, Neeraj Agarwal

Umang Swami

Umang Swami is an Assistant Professor in the Division of Oncology at the Huntsman Cancer Institute, University of Utah, specializing in medical oncology with a focus on genitourinary cancers. He earned his medical degree from Sawai Man Singh Medical College in India and gained research experience as a Visiting Scientist at the Montefiore-Einstein Cancer Center in New York, where he worked on phase I studies for advanced solid tumors.

Dr. Shilpa Gupta is the Director of Genitourinary Oncology, a staff member in Hematology and Oncology and a Professor of Medicine at Cleveland Clinic. Dr. Gupta’s extensive research focuses on novel drug development and biomarkers of response/resistance in bladder cancer, contributing to numerous published works and leadership roles in clinical trials.